<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01298687</url>
  </required_header>
  <id_info>
    <org_study_id>C-10-081</org_study_id>
    <nct_id>NCT01298687</nct_id>
  </id_info>
  <brief_title>Divided Dose of TRAVATAN®</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the incremental dosing of travoprost ophthalmic
      solution versus once a day dosing of TRAVATAN® in lowering intraocular pressure (IOP) in
      patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>24-hour Area Under the Curve (AUC) in IOP Reduction</measure>
    <time_frame>Day 5</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Trav 0.00013%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Ophthalmic Solution, 0.00013%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trav 0.00033%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Ophthalmic Solution, 0.00033%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trav 0.001%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Ophthalmic Solution, 0.001%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trav 0.00267%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Travoprost Ophthalmic Solution, 0.00267%, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TRAVATAN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Travoprost Ophthalmic Solution, 0.004%, 1 drop administered in each eye at 8 pm for 5 days, with 1 drop of vehicle administered at all other timepoints (2-hour intervals)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Travoprost vehicle, 1 drop administered in each eye 12 times per day at 2-hour intervals for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution, 0.00013%</intervention_name>
    <description>Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose</description>
    <arm_group_label>Trav 0.00013%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution, 0.00033%</intervention_name>
    <description>Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose</description>
    <arm_group_label>Trav 0.00033%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution, 0.001%</intervention_name>
    <description>Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose</description>
    <arm_group_label>Trav 0.001%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution, 0.00267%</intervention_name>
    <description>Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose</description>
    <arm_group_label>Trav 0.00267%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Ophthalmic Solution, 0.004%</intervention_name>
    <arm_group_label>TRAVATAN</arm_group_label>
    <other_name>TRAVATAN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Travoprost Vehicle</intervention_name>
    <description>Inactive ingredients used as an active comparator</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with open-angle glaucoma or ocular hypertension who meet the following IOP
             criteria:

               1. Mean IOP ≥ 24 mmHg in at least 1 eye, with the same eye qualifying at 8 AM at
                  both Day 0 and Day 1;

               2. Mean IOP ≤ 36 mmHg in both eyes at all time points on Day 0 and Day 1.

          -  Must sign an informed consent form.

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Females of childbearing potential who are pregnant, test positive on urine pregnancy
             test at the Screening Visit, intend to become pregnant during the study period, are
             breast-feeding, or are not using highly effective birth control measures.

          -  Current or history of ocular inflammation or infection in either eye within the past 3
             months.

          -  Corneal thickness greater than 620 µm as determined by pachymetry in either eye.

          -  Severe visual field loss.

          -  Cup to disc ratio greater than 0.8 in either eye.

          -  Intraocular surgery within the past 6 months in either eye.

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matt Walker, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 16, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <disposition_first_submitted>July 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>July 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 31, 2014</disposition_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>open-angle glaucoma</keyword>
  <keyword>ocular hypertension</keyword>
  <keyword>divided dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

